. Compared to Tamiflu, which requires two doses each day for five days, apparently only a single dose of Xofluza will be needed to treat the flu. Xohlu acts blocking the enonuclease enzyme acting at an earlier step before the virus has managed to replicate. Xofluza may need a year or two to reach the U.S. market. The new medicine will give doctors more options to fight a disease that kills as many as 650,000 people worldwide annually.
Shionogi has business roots that date back to 1878. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. With over 50 years of anti-infective research experience, Shionogi has helped to revolutionize the development of anti-bacterial and anti-viral treatments. As bacteria, pathogens, and other viruses adapt to resist existing treatments—causing millions of untreatable infections around the world—Shionogi is pursuing the development of novel treatments to combat this evolving threat,” is description of goals on their website.